Pharmacokinetics of the disialoganglioside, GD2, a circulating tumor biomarker for neuroblastoma, in nonhuman primates

• DOI: 10.33393/jcb.2021.2329
• Publication Date: 2021-12-06T11:25:35Z
• Authors: Frank M. Balis; Cynthia Lester Mc...; Christine M. Busch; Elizabeth Fox; Katherine E. Warren
• Keywords: Biomarker Discovery

Background: The ganglioside GD2 is a potential circulating tumor biomarker for the childhood cancer, neuroblastoma. Interpreting levels of depends in part on knowledge biomarker’s clinical pharmacology. cancer Methods: We studied plasma and cerebrospinal fluid (CSF) pharmacokinetics C18 lipoform two nonhuman primates with indwelling subcutaneous CSF lateral ventricular reservoir systems. was quantified validated high-performance liquid chromatography (HPLC)/tandem mass spectrometry assay. administered as short intravenous infusion frequent samples were drawn over 72 hours. Results: concentration declined monoexponentially half-life 16 Clearance 0.0136 0.0131 L/h volume distribution (Vd) 0.035 0.038 L/kg animals. Vd equivalent to volume. Greater than 98% bound form consistent its known association lipoproteins accounting limited distribution. did not cross from into CSF. Conclusions: pharmacokinetic profile favorable biomarker. This study demonstrates value characterizing pharmacology biomarkers better understand their behavior.